Chris Min

Chief Executive Officer & Chief Medical Officer • Longeveron

Kwan-Hong Chris Min joined Longeveron in April of 2022 and leads global clinical development and regulatory strategy for Longeveron’s investigational products. Dr. Min, a board-certified neurologist, brings to Longeveron over a decade of pharma and biotech clinical development experience. Most recently, Dr. Min served as VP and Head of Medical & Clinical Development at Enterin Inc. Prior to Enterin, he held positions at Cerevel as Head of Clinical Pharmacology, and at BlueRock Therapeutics as Senior Medical Director of Neurology, where he championed the clinical development process for pluripotent stem cell-derived dopaminergic neurons to treat Parkinson’s Disease. Dr. Min spent nearly 8 years in early clinical development at Merck Research Laboratories where he led the team that conducted a pivotal 375-subject Phase 1 safety study that led to FDA approval of Bridion®, a drug indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium, typically during surgery. 

Prior to his industry experience, Dr. Min served as a research clinician, faculty member, and attending physician at Columbia University Irving Medical Center and Harlem Hospital. Dr. Min earned an M.D. from the Weill Medical College of Cornell University, a Ph.D. in Biochemistry from The Rockefeller University and a A.B. in Biochemical Sciences from Harvard University. 

Also Speaking

Peter Francis

Chief Medical Officer & Chief Scientific Officer • Ray Therapeutics

Matthew Toomey

Director • Merit

Jenny Holt

Senior Vice President, Programme and Portfolio Management • Ray Therapeutics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.